552331-21-2

Usage

Uses

Used in Pharmaceutical and Medicinal Chemistry:
(5-bromo-2-fluorophenyl)(1H-pyrrol-2-yl)methanone is used as a building block for the synthesis of biologically active molecules due to its unique structural features. Its potential applications in this industry are attributed to the compound's ability to contribute to the development of novel drugs and therapeutic agents.
Used in Chemical Research:
In the field of chemical research, (5-bromo-2-fluorophenyl)(1H-pyrrol-2-yl)methanone serves as a subject of study to better understand its properties, reactivity, and potential interactions with other compounds. This research could lead to the discovery of new reactions or applications for the compound in various chemical processes.

Upstream product

• 773140-42-4 2-bromo-5-fluorobenzoyl chloride 
• 109-97-7 pyrrole 
• 146328-85-0 5-bromo-2-fluoro-benzoic acid 
• 93777-26-5 5-bromo-2-fluorobenzaldehyde 

Relevant academic research and scientific papers

Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors

A series of heteroaryl-pyridine containing inhibitors of Akt are reported. The synthesis and structure-activity relationships are discussed, leading to the discovery of a indazole-pyridine analogue (Ki = 0.16 nM). These compounds bind in the ATP binding site, are potent, ATP competitive, and reversible inhibitors of Akt activity. No selectivity amongst the Akt isoforms is observed for this analogue, but there is good selectivity against an panel of other kinases. It is least selective for other members of the AGC family of kinases but is nonetheless 40-fold selective for Akt over PKA. The compound shows cellular activity and significantly slows tumor growth in vivo.

Kinase inhibitors

Compounds having the formula are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.

Kinase inhibitors

Compounds having the formula are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.